Cormorant Asset Management, LP 89bio, Inc. Transaction History

Cormorant Asset Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $20.5 Million - $31.9 Million	-1,450,000 Reduced 51.79%	1,350,000 $25.6 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $2.62 Million - $4.24 Million	250,000 Added 9.8%	2,800,000 $42.6 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $14.1 Million - $32.5 Million	2,550,000 New	2,550,000 $32.5 Million

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.